Transition from ziprasidone im to oral formulation in agitated patients with acute exacerbation of schizophrenia: An open trial

Pharmacopsychiatry

Volumn 44, Issue 5, 2011, Pages 173-178

  Mautone, A ^a   Scarone, S ^b  

^a Psychiatric Service for the Diagnosis and Treatment   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

acute exacerbation; antipsychotic agents; schizophrenia; transition; ziprasidone

Indexed keywords

ZIPRASIDONE;

ADULT; AGITATION; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG FORMULATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOPHRENIA; TREATMENT DURATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMOTOR AGITATION; SCHIZOPHRENIA; THIAZOLES;

EID: 80051793582     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0031-1280794     Document Type: Article

References (19)

1. Lesem MD, Zajecka JM, Swift RH et al. Intramuscular ziprasidone, 2mg versus 10mg, in the short-term management of agitated psychotic patients. J Clin Psychiatry: 2001; 62 12 18 (Pubitemid 32154312)
2. Nordstrom K, Allen MH. Managing the acutely agitated and psychotic patient. CNS Spectr: 2007; 12 10 Suppl. 17 5 11 (Pubitemid 350099579)
3. Zimbroff DL, Allen MH, Battaglia J et al. Best clinical practice with ziprasidone IM: update after 2 years of experience. CNS Spectr: 2005; 10 1 15 (Pubitemid 41443046)
4. Preval H, Klotz SG, Southard R et al. Rapid-acting IM ziprasidone in a psychiatric emergency service: a naturalistic study. Gen Hosp Psychiatry: 2005; 27 140 144 (Pubitemid 40348779)
5. Caas F, Prez-Sol V, Daz S et al. ZIMO Trial Collaborative Group. Cost-effectiveness analysis of ziprasidone versus haloperidol in sequential intramuscular/oral treatment of exacerbation of schizophrenia: economic subanalysis of the ZIMO trial. Clin Drug Investig: 2007; 27 633 645
6. Brook S. Intramuscular ziprasidone: moving beyond the conventional in the treatment of acute agitation in schizophrenia. J Clin Psychiatry: 2003; 64 19 13 18
7. Gillies D, Beck A, McCloud A et al. Benzodiazepines alone or in combination with antipsychotic drugs for acute psychosis. Cochrane Database Syst Rev: 2005; 4 CD003079
8. Maguire GA. Comprehensive understanding of schizophrenia and its treatment. Am J Health Syst Pharm: 2002; 59 17 Suppl. 5 S4 S11 (Pubitemid 34971265)
9. Caas F. Management of agitation in the acute psychotic patient efficacy without excessive sedation. Eur Neuropsychopharmacol: 2007; 17 02 S108 S114
10. Swainston Harrison T, Scott LJ. Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder. CNS Drugs: 2006; 20 1027 1052 (Pubitemid 44920139)
11. Greenberg WM, Citrome L. Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials. CNS Drug Rev: 2007; 2 137 177 (Pubitemid 47052346)
12. Brook S, Lucey JV, Gunn KP. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Ziprasidone I.M. Study Group. J Clin Psychiatry: 2000; 61 933 941 (Pubitemid 32058009)
13. Daniel DG, Potkin SG, Reeves KR et al. Intramuscular (IM) ziprasidone 20mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology (Berl): 2001; 155 128 134 (Pubitemid 32417820)
14. Daniel DG, Zimbroff DL, Swift RH et al. The tolerability of intramuscular ziprasidone and haloperidol treatment and the transition to oral therapy. Int Clin Psychopharmacol: 2004; 19 9 15 (Pubitemid 38114618)
15. Brook S, Walden J, Benattia I et al. Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study. Psychopharmacology (Berl): 2005; 178 514 523 (Pubitemid 40486992)
16. Jangro WC, Preval H, Southard R et al. Conventional intramuscular sedatives versus ziprasidone for severe agitation in adolescents: case-control study. Child Adolesc Psychiatry Ment Health: 2009; 3 9
17. Rais AR, Williams K, Rais T et al. Use of intramuscular ziprasidone for the control of acute psychosis or agitation in an inpatient geriatric population: an open-label study. Psychiatr (Edgmont): 2010; 7 17 24
18. Shu L, Zhang H, Wang G et al. Intramuscular ziprasidone has improved tolerability over haloperidol and comparable efficacy for control of agitation in Chinese patient with schizophrenia. Schizophrenia International Research Society (SIRS) Congress 1014 April: 2010; Florence, Italy
19. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs: 2007; 21 911 936 (Pubitemid 47557106)